Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / HALO - Halozyme Therapeutics: Low Risk Buy And Hold

HALO - Halozyme Therapeutics: Low Risk Buy And Hold

Halozyme Therapeutics Inc.
  • Low risk biotech with steadily increasing revenue and earnings from ENHANZE drug delivery.
  • Revenue and earnings are expected to peak at end of the decade with a long tail into the mid-2030s.
  • Sizeable earnings provide ample cash for acquisitions or partnerships that will likely keep earnings growing beyond this decade.
  • HALO is undervalued given the low-risk nature of the business and annual EPS earnings growth of 15-20%.
  • Recommendation: long-term buy and hold.

For further details see:

Halozyme Therapeutics: Low Risk Buy And Hold
Stock Information
Company Name: Halozyme Therapeutics Inc.
Stock Symbol: HALO
Market: NASDAQ
Website: halozyme.com
Menu
HALO HALO Quote HALO Short HALO News HALO Articles HALO Message Board
Get HALO Alerts

News, Short Squeeze, Breakout and More Instantly...